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Abstract: Synovial sarcoma (SS) is an aggressive malignancy which accounts for approximately 5–10%
of all soft-tissue sarcomas. SS has pathologic and genomic characteristics that define it as a distinct
subtype of soft tissue sarcoma (STS). STS subtypes continue to be recognized as distinct entities
with specific characteristics, including differential chemo-sensitivity. The objective of this study
was to conduct a descriptive review of current data on survival outcomes of systemic anti-cancer
therapy specific to SS. A systematic literature review was conducted, using a custom search strategy
to search EMBASE, Medline and CENTRAL for clinical trials and observational studies reporting
overall survival (OS), progression-free survival (PFS) and/or response for cohorts of at least 50 SS
patients. We identified 28 studies meeting these criteria, 25 of which were retrospective studies. Only
three prospective studies were identified. Survival reports varied widely between studies based on
the population, in particular on the disease stage, and reporting was heterogeneous in terms of the
time points reported on. For patients with localized disease, reports of five-year PFS ranged from
26% to 80.7% and five-year OS from 40% to 90.7%, whereas five-year OS for patients with metastatic
disease was very low at around 10%; and in one case, 0% was reported. Only four of the included
publications reported outcomes by type of systemic anti-cancer therapy received. Our study draws
attention to the fact that additional prospective studies to better define the most appropriate treatment
for SS in all stages and lines of therapy are still needed.
Keywords: synovial sarcoma; survival; chemotherapy; systemic anti-cancer therapy; systematic
review
1. Introduction
There is limited differentiation in treatment guidelines between soft tissue sarcoma (STS)
subtypes [1,2]. However, distinct subtypes with specific characteristics are being recognized; features
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that distinguish subtypes include morphology, immunohistochemistry, genomics, molecular profile
and clinical features [3]. Identifying histology-specific treatment is important where STS subtypes
are being classified and treated based on molecular and genetic characteristics as well as differential
natural history and chemosensitivity [3,4]. Currently, there is no systemic anti-cancer therapy approved
specifically for synovial sarcoma (SS).
SS is an aggressive malignancy which accounts for approximately 5–10% of all STS [5–8].
The estimated incidence of SS is 1.5 per 1,000,000 in the US and 1.4 per 1,000,000 in the UK [7,9–11]. It
is the most common non-rhabdomyosarcoma STS in children and young adults [8]. Approximately
one-third of SS occurs in childhood, but peak incidence is in the third decade of life [12]. SS frequently
arises in the extremities, but can also develop from serosal surfaces of almost any part of the body such
as the pleura or pericardium [7,8].
SS has unique pathologic and genomic characteristics including histologic subtypes, biphasic and
monophasic, and a characteristic translocation, t(X;18)(p11.2;q11.2) [13]. Other genomic characteristics
such as the B-cell lymphoma 6 co-repressor (BCOR) upregulation and the immunoreaction of the
nuclear tumor suppressor gene SMRRCB1/INI1 (INI1) were not found to be associated with a worse
prognosis [14,15]. SS is one of the most common STS subtypes to express NY-ESO-1; greater than 80%
of synovial tumors express NY-ESO-1, which is associated with worse prognosis [16–20].
There are no approved systemic therapies that target these histologic or genomic characteristics.
Surgical resection is the standard treatment for localized SS, with consideration for use of
neoadjuvant/adjuvant radiation and/or systemic anti-cancer therapy [7,21]. Prognosis for
non-metastasized patients is often favorable for tumors <5 cm resected with adequate margins [22];
local recurrence occurs in approximately 17% of patients [14]. Metastatic disease is present in
approximately 24% of the patients at diagnosis [14]. SS is associated with local recurrence and
distant metastases. Metastases occur in 50–70% of cases [23]; most metastases develop in the lungs
(80%), followed by bone (10%) and liver (5%) [5]. Locally advanced or metastatic SS tends to be treated
initially with systemic anti-cancer therapy [24], however, there is no consensus regarding the most
appropriate therapy regimen or sequence. The prognosis of patients with metastatic SS is limited
regardless of treatment [25].
Treatment decisions for SS are informed by clinical features and published data obtained from
trials that enrolled multiple STS subtypes. These trials were not designed to evaluate the impact of
systemic anti-cancer therapy on a specific histologic subtype. This makes it difficult to evaluate the
potential benefit for a specific histology such as SS.
No systematic overview of survival outcomes achieved with systemic anti-cancer therapy across
studies specific to SS currently exists. The objective was to conduct a systematic literature review (SLR)
of current published data on survival outcomes and responses to systemic anti-cancer therapy in SS.
This review can serve to support development of future research and inform guidelines specific to SS
using currently available anti-cancer therapies.
2. Materials and Methods
Methodology for the SLR was consistent with recommendations published in the Preferred
Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement and by the Centre
for Reviews and Dissemination [26,27].
2.1. Search Strategy and Study Selection
The search for peer-reviewed literature was limited to studies published in 2000 or later to evaluate
the effect of systemic anti-cancer therapy on SS in the modern era. The following electronic databases
were searched via the OVID search portal: Embase, MEDLINE, and the Cochrane Central Register
of Controlled Trials (2000 to 30 January 2018). Search strategies are provided in the supplementary
material (Table S1). In addition, conference proceedings were searched for 2015–2017 for the following
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conferences: American Society of Clinical Oncology (ASCO), European Society of Medical Oncology
(ESMO), and Connective Tissue Oncology Society (CTOS) Annual Meeting.
All abstracts and full text articles were reviewed according to the pre-specified eligibility criteria,
outlined in Table 1, by two independent reviewers (Reviewers: JT, KM, ZK). Any studies where the
reviewers disagreed on inclusion at either selection stage were referred to a third independent reviewer
for a final decision. A PRISMA flow diagram (Figure 1) was developed indicating the numbers of
studies included and excluded at each stage of the review.
Table 1. Eligibility criteria.
Patients Patients with reported SS (adult or pediatric)
Interventions/Comparators Systemic anti-cancer therapy
Outcomes
OS, PFS, response (including overall, complete and partial
response and stable and progressive disease), duration of response,
time to next treatment
Study Design
Clinical trials (randomized or non-randomized) or observational
study, excluding case reports and case series; minimum number of
SS patients: 50
Geography/Language Europe, North America, Japan, Australia or New Zealand;published in English
Publication Year 2000–2018
SS: Synovial Sarcoma, OS: Overall survival, PFS: Progression free survival.
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2.2. Data Extraction
Data were captured in an Excel® (Microsoft) extraction template (included in the Supplementary
Material) by a single reviewer and were independently validated by a second reviewer (Reviewers:
Juliette Thompson, Kerstin Mueller, Zaeem Khan). Extracted data included study characteristics
(study design, follow-up periods, and main inclusion/exclusion criteria), patient characteristics (mean
age, sex distribution, prior therapies, disease stage, performance status, histology, and tumor size),
treatment details, and efficacy endpoints (overall survival, progression-free survival, tumor response).
2.3. Data Analysis
Data were synthesized in tabular format; efficacy outcomes were stratified by age, histology,
treatments, or by localized or advanced/metastatic disease when available in the publication. Overall
survival (OS) and progression-free survival (PFS) were the primary outcomes of interest.
3. Results
A total of 3198 abstracts were identified in the search, and 28 met the inclusion criteria for this
review (Figure 1). Of the included publications, 25 were retrospective studies reporting between 51
and 1318 SS patients, including a retrospective analysis of data from 15 clinical trials (9 Phase II, 2
Phase II/III and 4 Phase III) published between 1987 and 2015 [28], and three were prospective studies
(two trials [1 phase III, 1 undefined] and one observational study) reporting between 70 and 188 SS
patients (Table 2). The objectives of the included publications are listed in the supplementary material
(Table S2).
Despite the majority of publications being retrospective studies, most indicated SS was
histologically or pathologically confirmed in the study sample. Only four studies indicated whether
immunohistochemical results were required or recommended for diagnosis [12,29–31]. Only one study
indicated classification of STS based on ICD-codes [32] only; the risk of misclassification was noted [33].
One publication discussed how histological review altered diagnosis for patients, 2/94 patients had
been misdiagnosed [12]. Details of SS diagnosis was not provided in four studies [28,34–36].
Sixteen of 28 studies focused on localized disease [4,12,23,31,34–43], 10/28 studies included
both localized and metastatic disease [11,25,28–30,44–48], and 2/28 studies focused on metastatic
disease [49,50] (Table 1). Definitions of disease status were infrequently reported; generally just stating
whether the population included was either localized or non-metastatic without staging information.
Six studies reported disease stage at the start of the study. Details on whether patients were considered
resectable were reported in 14 studies (Table 3). Of the included studies, eight were conducted in
North America [4,23,33,34,39,42,45,48], 15 in Europe [11,25,28,29,31,35–38,40,41,43,46,47,49,50], two
in Japan [30,44], and two were multi-regional [12,51]. Length of study follow-up ranged from 12.3
months [51] to 11.4 years (137 months) [38] for localized disease and from 51 months [44] to 78
months [45] for metastatic disease (Table 2).
Baseline characteristics of patients were heterogeneous (Table 3): median age ranged from
12 [36,41] to 42.5 years [29] and 26.7% [34] to 63% were female [42]. Monophasic tumors accounted
for 18% [31] to 85% [42] and biphasic tumors for 15% [42] to 77% [31] of tumors. Primary tumors in
the upper extremities ranged from 13% [34] to 37% [4] and in the lower extremities from 33% [34] to
85% [4].
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Table 2. Included studies and their characteristics.
Author, Publication Year Country Number of Participants Study Design Follow-Up in Months Median (Range)
Localized
de Silva, 2004 [31] Scotland 51 Retrospective, Cohort 99
Scheer, 2016 [37] Germany 52 Retrospective, Cohort –
Krieg, 2011 [38] Switzerland 62 Retrospective, Cohort 136.8 (3.6–331.2)
Beaino, 2016 [23] USA 63 Retrospective, Cohort 85 * (13–210)
Orbach, 2011 [36] Europe 88 Retrospective, Cohort 102 (3–168)
Shi, 2013 [39] USA 92 Retrospective, Cohort 62.4
Eilber, 2007 [4] USA 101 Retrospective, Cohort 58 (12–185)
Al-Hussaini, 2011 [34] Canada 102 Retrospective, Cohort 67.2 (3.1–216)
Trassard, 2001 [40] France 128 Retrospective, Cohort 128
Ferrari, 2015 [12] Multi-national 138 Prospective trial 52.1 (13.8–104.4)
Brecht, 2006 [41] Germany, Italy 150 Retrospective, Cohort 80 (6–250)
Italiano, 2009 [35] France, Switzerland 237 Retrospective, Cohort 58 (1–321)
Canter, 2008 [42] USA 255 Retrospective, Cohort 72 (0–287)
Vlenterie, 2015 [43] Netherlands 461 Retrospective, Cohort –
Vining, 2017 [33] USA 544 Retrospective, Cohort 49.2
Gronchi, 2017 [51] France, Italy, Poland, Spain 70 † Prospective trial 12.3
Locally advanced or metastatic
Takenaka, 2008 [30] Japan 108 Retrospective, Cohort 54
Setsu, 2013 [44] Japan 112 Retrospective, Cohort 51
Deshmukh, 2004 [45] USA 135 Retrospective, Cohort 78 (20–420)
Guillou, 2004 [29] France, Switzerland, Belgium 165 Retrospective, Cohort 37 (2–302)
Palmerini, 2009 [46] Italy 250 Retrospective, Cohort 66
Ferrari, 2004 [47] Italy 271 Retrospective, Cohort 65 (12–250)
Vlenterie, 2016 [28] Europe 313 Retrospective, Cohort –
Brennan, 2016 [11] England 1318 Retrospective, Cohort –
Corey, 2014 [48] USA 3756 Retrospective, Database –
Spurrell, 2005 [25] UK 104 Retrospective, Cohort –
Metastatic disease
Sanfilippo, 2015 [49] Italy, France, UK 61 Retrospective, Cohort –
Savina, 2017 [50] France 188 † Prospective, Cohort 61 (1–300)
Abbreviations: ‘–’ = Not reported; * mean reported rather than median; † specifically SS patients.
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Treatments (%) SS Histology (%) Primary Tumor Site (%)
Resectable




de Silva, 2004 [31] All SS patients 51 33 (9–77) 49 25 27 100 18 77 92 – 75 100
Scheer, 2016 [37] All SS patients,pediatric and adolescent 52 13.9 (0.9–20.9) 46 73 94 100 65 33 – – – –
Krieg, 2011 [38] All SS patients 62 – (6–82) 58 – – – 56 44 76 – – –
Beaino, 2016 [23] All SS patients 63 33 (4–74) 59 56 14 – 59 38 17 57 100
Orbach, 2011 [36] All SS patients,pediatric and adolescent 88 12 (2–17) 47 – 93 74 – – – 20 46 –
IRS I + Tumor size ≤ 5 17 – – 12 65 88 – – – – – –
IRS I + Tumor size > 5 4 – – – 100 100 – – – – – –
IRS II + Tumor size ≤ 5 16 – – 13 88 94 – – – – – –
IRS II + Tumor size > 5 12 – – 33 92 92 – – – – – –
IRS III 39 – – 56 97 79 – – – – – –
Shi, 2013 [39] All SS patients 92 35.3 50 – 23 – – – – 24 58 100
Eilber, 2007 [4] All SS patients 101 34 (16–75) 51 95 67 – 68 32 – 30 70 –
IFO-based 68 33 (16–64) 54 97 100 – 68 32 – 37 63 –
No chemo 33 38 (17–75) 46 91 0 – 70 30 – 15 85 –
Al-Hussaini, 2011 [34] All SS patients - - 45 78 25 100 – – – 27 57 100
Adult patients 87 37.6 (15–76) 48.3 83 14 100 – – – 30 60 100
Pediatric patients 15 14 (0.4–18) 26.7 53 87 100 – – – 13 33 100
Trassard, 2001 [40] All SS patients 128 33 (15–76) 58 80 57 99 57 35 76 – – 99.2
Ferrari, 2015 [12] All SS patients,pediatric and adolescent 138 13.7 44 – – – – – – – – –
IRS I, tumor < 5 cm, no
chemo 24 – – – – 100 – – – – – –
IRS 1 tumor > 5 cm or
IRSII, three to six
courses of adjuvant
chemo and RT
37 – – – – – – – – – – –
IRS III or N1 tumor, six
courses of chemo,
delayed surgery, RT
77 – – – – – – – – – – –
Brecht, 2006 [41] All SS patients,pediatric and adolescent 150 12 (1–21) 45 71 97 51 41 35 84 – – 50.7








Treatments (%) SS Histology (%) Primary Tumor Site (%)
Resectable
(%)Median (Range) RT Chemo Surgery MonophasicBiphasic Extremities UpperExtremities
Lower
Extremities
Italiano, 2009 [35] All SS patients 237 35 (15–76) 51 – – 100 – – – 21 65 100
Canter, 2008 [42] All SS patients 255 34 50 – – – 66 34 – 23 58 –
SYT-SSX1 73 41 (16–80) 36 66 47 – 56 44 – 20 59 –
SYT-SSX2 59 35 (18–78) 63 75 40 – 85 15 – 19 56 –
Vlenterie, 2015 [43] All SS patients 461 38 (2–89) 46 – – – 22 24 66 – – 90.2
Vining, 2017 [33] All SS patients 544 42 (29–55) 49.5 – – – 41.5 22.6 – 18.4 47.2 100




34 – – – – – – – – – – 100
Mixed population (localized and metastatic)
Takenaka, 2008 [30] All SS patients 108 37 (8–74) 59.3 21 77 93 63 30 67 – – 96.3
Setsu, 2013 [44] All SS patients 112 – 61 15 24 – 67 29 – – – –
Deshmukh, 2004 [45] All SS patients 135 31 (8–81) 37 71 38 90 – – – 16 65 –
Palmerini, 2009 [46] Metastatic 46 40 (13–79) 39 – – 89 74 22 – – – –
Localized 204 36 (7–83) 54 – 48 100 60 36 – – – –
Ferrari, 2004 [47] All SS patients 271 32 (5–87) 47 – 41 – 38 43 22 63 –
Vlenterie, 2016 [28] All SS patients 313 40 (18–81) 39 41 100 43 – – 56 14 41 –
Brennan, 2016 [11] All SS patients 1318 – 48 – – 71 – – 65 – – –
Adults 1136 – 48 – – 70 – – 66 – – –
Children and
adolescents 182 – 43 – – 77 – – 63 – – –
Corey, 2014 [48] SS, biphasic 732 40 47 – – – – 100 – – – –
SS, histology not
specified 1820 41 48 – – – – – – – – –
SS, spindle cell 1204 41 49 – – – – – – – – –
Spurrell, 2005 [25] All SS patients 104 33 50 67 30 87 40 38 66 18 48 –
Metastatic disease
Sanfilippo, 2015 [49] All SS patients 61 37 (18–68) 58 – 100 – – – 57 – – 0
Savina, 2017 * [50] All SS patients 188 – – – – – – – – – – –
Abbreviations: ‘–’ = Not reported; IFO = Ifosfamide; IRS = Intergroup Rhabdomyosarcoma Staging; SS = Synovial sarcoma. * baseline characteristics only provided for total STS population.
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Radiotherapy was received by 12% to 97% of patients in the localized setting [4,36], only one
study reported radiotherapy use in metastatic patients (58%) [49]. Where reported, radiotherapy was
received at a median dose of 45–65 Gy. [34,36,39,41,47]. Those receiving systemic anti-cancer therapy
ranged from 14% for adult patients with localized SS [34] to 100% in the metastatic setting [49]. In
the localized disease setting, between 51% [41] and 100% [34,35,37,46] of patients underwent surgery
(Table 3).
Our study focused on outcomes with the use of systemic anti-cancer therapy. Only four of the
included publications (Vlenterie [28], Ferrari [47], Gronchi [51], Sanfillipo [49]) reported outcomes by
the type of systemic anti-cancer therapy. Other publications simply reported the proportion of patients
receiving systemic anti-cancer therapy for which outcomes were reported.
PFS and OS outcomes were assessed using various definitions, imaging methods and follow-up
periods at varying time points between the individual studies (Table 4). Among 11 studies reporting
PFS, the endpoint was defined in eight studies as the time between diagnosis, study registration, or
randomization and the latest date of event-free follow-up, disease progression, recurrence, or death.
No definition of PFS was provided in three studies. OS was reported by 20 studies, of which only nine
provided a definition as the time between diagnosis, study registration, randomization, or treatment
initiation and the reported death date or last known date of follow-up. Most publications reported
proportions of surviving patients at specific time points. Only six publications reported median
follow-up durations for survival outcomes.
Table 4. Survival outcomes.
Study ID Population N
PFS OS




% OS (95% CI) Median, Months(95% CI)
Localized
Time point 1 year
Italiano, 2009 [35] All SS patients 237 – – 85 (82, 88) 136 (70, 204)
Time point 3 years
Ferrari, 2015 [12] Tumor site-axial 39 77.7 (60.2–88.2) – 100 (-) –
Tumor site-extremities 99 83.8 (74.4–89.9) – 96 (88.2–98.7) –
Time point 5 years
de Silva, 2004 [31] All SS patients 51 – – 56 (-) 40.1 (-)
Scheer, 2016 [37]
All SS patients 52 26 (-) – 40 (-) –
Tumor site-axial 11 18.2 (-) – 22.7 (-) –
Tumor site-non-axial 41 28.4 (-) – 44.7 (-) –
Krieg, 2011 [38]
All SS patients 62 – – 74.2 (-) –
FNCLCC Grade 2 32 – – 97 (-) –
FNCLCC Grade 3 11 – – 18 (-) –
Orbach, 2011 [36] All SS patients, pediatric 88 68 (-) – 85 (-) –
Shi, 2013 [39]
All SS patients 92 56 (-) – 61 (-) –
Chemo 21 67 (-) – 65 (-) –
No Chemo 71 49 (-) – 53 (-) –
Tumor site-extremities 75 57 (-) – 60 (-) –
Tumor site-trunk 11 52 (-) – 63 (-) –
Al-Hussaini, 2011 [34]
All SS patients 102 69.3 (-) – 80.3 (-) –
Adult 87 68.3 (-) – 76.9 (-) –
Pediatric 15 74.9 (-) – 100 (-) –
Chemo (all SS patients) 25 62.6 (-) – – –
No Chemo 77 71.5 (-) – – –
Ferrari, 2015 [12] All SS patients 138 80.7 (72.5, 86.7) – 90.7 (82, 95.3) –
Brecht, 2006 [41]
All SS patients 150 77 (-) – 89 (-) –
Tumor site-extremities 129 79 (-) – 90 (-) –
Tumor site-other (not
extremities) 21 68 (-) – 88 (-) –
Tumor status-T1 94 88 (-) – 96 (-) –
Italiano, 2009 [35] All SS patients 237 – – 64 (59, 69) –
Vlenterie, 2015 [43] All SS patients 461 – – 63.5 (-) –
Takenaka, 2008 [30] Localized 91 – – 81 (-) –
Deshmukh, 2004 [45] Localized (primary +locally recurrent) 108 – – 69 (-) –
Palmerini, 2009 [46] Localized 204 58 (51, 66) – 76 (69, 82) –
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Table 4. Cont.
Study ID Population N
PFS OS




% OS (95% CI) Median, Months(95% CI)
Time point 9 years
Italiano, 2009 [35] All SS patients 237 – – 46 (40, 52) –
Time point 10 years
de Silva, 2004 [31] All SS patients 51 – – 45 (-) –
Krieg, 2011 [38]
All SS patients 62 – – 61.2 (-) –
FNCLCC Grade 2 32 – – 84 (-) –
FNCLCC Grade 3 11 – – 0 (-) –
Shi, 2013 [39]
All SS patients 92 53 (-) – 56 (-) –
Chemo 21 67 (-) – 65 (-) –
No Chemo 71 49 (-) – 48 (-) –
Tumor site-extremities 75 55 (-) – 55 (-) –
Tumor site-trunk 11 41 (-) – 63 (-) –
Brecht, 2006 [41] All SS patients 150 89 (-) – 78 (-) –
Vlenterie, 2015 [43] All SS patients 461 – – 53.8 (-) –
Deshmukh, 2004 [45]
All SS patients 108 – – 51 (-)
Localized (primary +
locally recurrent) 108 – – 51 (-) –
Mixed population localized/locally advanced / metastatic
Time point 2 years
Corey, 2014 [48] SS, biphasic 732 – – 85 (-) –
SS, NOS 1820 – – 71 (-) –
SS, spindle cell 1204 – – 77 (-) –
Time point 1 year
Vlenterie, 2016 [28] All SS patients 313 18.7 (14.6, 23.3) 6.3 (5.9, 7.0) 63.7 (57.9, 68.8) 15 (13.9, 16.4)
Anthracycline 121 17.5 (11.2, 24.9) 5.06 (4.3, 6.1) 62.6 (53.1, 70.8) 14.85 (12.2, 16.2)
Dox + IFO 112 21.4 (14.4, 29.4) 7.47 (6.5, 8.7) 66.3 (56.7, 74.3) 14.98 (12.9, 18.9)
CYVADIC 30 23.3 (10.3, 39.4) 6.08 (3.0, 10.8) 58.6 (38.7, 74.1) 15.8 (8.4, 23.1)
IFO 42 15.5 (6.4, 28.5) 7.2 (5.9, 9.2) 65.6 (48.9, 78) 15.34 (11.7, 19.7)
Other chemotherapy 8 0 (-) 2.27 (1.0, 9.0) 29.2 (1, 71.9) 10.45 (0.9, NR)
Tumor site-extremity b 174 16.1 (11–21.9) 6.21 (5.3–7.1) 63.1 (55.3–69.69) 15.5 (13.3–18.1)
Tumor site-other c 52 22.0 (11.9–34.2) 7.13 (5.1–8.9) 63.6 (48.6–75.3) 14.4 (11.6–18.7)
Time point 3 years
Ferrari, 2015 [12] IRS I, tumor <5 cm, nochemo 24 91.7 (70.6, 97.8) – 100 (-) –
IRS 1 tumor >5 cm or IRSII,
three to six courses of
adjuvant chemo and RT
37 91.2 (75.1, 97.1) – 100 (-) –
IRS III or N1 tumor, six
courses of chemo, delayed
surgery, RT
77 77.7 (60.2–88.2) – 100 (-) –
Time point 5 years
Takenaka, 2008 [30]
All SS patients 108 – – 69.8 (-) –
Tumor site-extremities 72 – – 57.4 (-) –
Tumor site-trunk 36 – – 78.1 (-) –
Setsu, 2013 [44]
All SS patients 65 – 24 (-) 62 (-) –
Tumor site-distal
extremities 39 48.3 (-) – 79.8 (-) –
Tumor site-proximal
extremities 63 36.5 (-) – 50.9 (-) –
Deshmukh, 2004 [45] All SS patients 135 – – 61 (-) –
Palmerini, 2009 [46]
All SS patients - – – 68 (-) –
Tumor site-lower
extremities - 59 (-) – 75 (-) –
Tumor site-upper
extremities - 76 (-) – 78 (-) –
Ferrari, 2004 [47] All SS patients 271 36.8 (-) – 64.3 (-) –
Adjuvant chemo 61 55.3 (-) – 71.5 (-) –
No adjuvant chemo 154 35.2 (-) – 70.3 (-) –
IFO + Dox/Epi - 52.3 (-) – – –
Other chemo - 59.4 (-) – – –
Locally advanced disease a 40 31.9 (-) – 49.6 (-) –
Corey, 2014 [48] SS, biphasic 732 – – 65 (-) –
SS, histology not specified 1820 – – 52 (-) –
SS, spindle cell 1204 – – 56 (-) –
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Table 4. Cont.
Study ID Population N
PFS OS




% OS (95% CI) Median, Months(95% CI)
Time point 10 years
Deshmukh, 2004 [45]
All SS patients 135 – – 42 (-) –
Primary tumor 99 – – 55 (-) –
Local recurrence 9 – – 11 (-) –
Ferrari, 2004 [47] All SS patients 271 29.8 (-) – – –
Time point not reported
Spurrell, 2005 [25] All SS patients 104 – – – 22 (-)
Metastatic disease
Time point 0.5 years
Sanfilippo, 2015 [49] All SS patients 61 23 (-) 3 (-) – –
Time point 5 years
Takenaka, 2008 [30] Metastatic 17 – – 0 (-)
Palmerini, 2009 [46] Metastatic 46 – – 10 (-) –
Brecht, 2006 [41] Tumor status-T2 53 60 (-) – 78 (-) –
Savina 2017 [50] Metastatic 188 7.14 (-) 19.7 – –
Time point 10 years
Deshmukh, 2004 [45] Metastatic 27 – – 15 (-) –
Abbreviations: ‘–’ = Not reported; CYVADIC = Cyclophosphamide, vincristine, adriamycin and DTIC;
Dox + IFO = Doxorubicin and ifosfamide; Ifo + Dox/Epi = Ifosfamide and doxorubicin or epirubicin. a Considered
unresectable at diagnosis; b Consisting of lower and upper extremities; c Consisting of trunk, head and neck,
abdominal, thorax, gastrointestinal, skin, visceral gynecological, and other.
3.1. Localized Disease
Two studies reported treatment responses in patients with localized disease, one of which was
response to surgery rather than systemic anti-cancer therapy, so was not considered relevant [36].
Al-Hussaini reported that one of 10 adult patients achieved a partial response and in the pediatric
population two of 5 patients achieved response using the RECIST criteria (one partial, one
complete) [34].
Among the publications reporting survival data for patients with localized disease, three-year
PFS rates were reported by Ferrari (2015), ranging from 91.7% to 91.2% [12]. Three-year OS among the
same patient subgroups were both 100%. Reports of five-year PFS ranged from 26% [37] to 80.7% [12]
and five-year OS from 40% [37] to 90.7% [12]. Ten-year PFS was reported by two studies and ranged
between 53% [39,47] and 89% [41]. Ten-year OS was reported by six studies and ranged from 51% [45]
to 78% [41] (Table 4).
Generally in studies of localized disease, patient outcomes were only reported for the whole study
cohort and by disease stage at diagnosis (Table 4). Typically, grade 3 disease was associated with a
shorter PFS and OS compared to grade 1 or 2 disease. Deshmukh reported a five-year PFS of 70%
for grade 1 or 2 disease versus 55% for grade 3 disease [45]. Similarly, Kreig reported a five-year OS
of 97% for grade 2 patients compared to 15% for grade 3 patients [38]. Vining observed a significant
risk of mortality in patients with grade 3 disease compared to grade 1 or 2 (hazard ratio: 2.32, 95%
confidence interval: 1.46–3.67; p < 0.001) [33]. In addition to the overall estimates of PFS reported
(81.9% at 3 years), Ferrari provided results for patients in low (IRS group I, ≤5 cm tumor: 91.7%
at 3 years) and intermediate (IRS group I, >5 cm tumor and all IRS group II: 91.2% at 3 years) risk
groups [12]. Similarly, Al-Hussaini provided results for the adult (five-year PFS: 68.3%) and pediatric
(five-year PFS: 74.9%) populations separately as well as combined (five-year PFS: 69.3%) [34].
Two retrospective studies reported OS for localized disease. Median OS in patients that underwent
resection/amputation was 40.1 months (3.3 years) for patients treated between 1955 and 1999, all of
which were classified as FNCLCC grade 3 [31]. Median OS in Italiano was 136 months (11.3 years)
for patients with completely resected localized SS; 47.2% of these patients were classified as FNCLCC
grade 3 [35].
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3.2. Mixed Population (Locally Advanced and Metastatic Disease)
Four studies of mixed populations reported response to treatment, which was generally a
combination doxorubicin (Dox) + Iifosfamide (Ifo). In Ferrari, overall response was 56% in patients
receiving Dox or epirubicin+Ifo compared to 31% in patients treated with “other” chemotherapy as
any line of treatment [47]. In Setsu, 20% of patients treated with primarily Ifo-based adjuvant or
second-line therapy achieved a partial response [44].
Spurrell examined responses using radiology reports on patients treated from 1978–2003.
Response to chemotherapy was recorded via retrospective viewing of radiology reports (most reports
using Response Evaluation Criteria In Solid Tumors [RECIST], but historical reports using World
Health Organization [WHO] criteria). They found that out of 92 patients that received first-line
chemotherapy for advanced disease (metastatic, local recurrence not amenable to complete excision or
primary tumor not amenable to excision), 38 had a response (Dox + Ifo: n = 18/30; Dox: n = 6/25; Ifo:
n = 4/25).
However, the details for those responses are not provided and 35 of the 92 patients had
metastectomies which may have confounded response assessments [25]. Median OS for the total
population in this study was 22 months [25].
Vlenterie reported a retrospective analysis of outcomes for cohorts of SS subjects enrolled across
15 prospective clinical trials in first-line systemic treatment for advanced STS published between 1987
and 2015. Treatment response using WHO or RECIST ranged between 21.5% and 33.3%; complete
response was highest in CYVADIC (cyclophosphamide, vincristine, adriamycin, DTIC) treated patients
(10%, n = 30), however, a similar complete response rate was observed for the larger cohort available
for Dox + Ifo (n = 112, CR: 6.3%) [28]. The publication reported 27.8% of SS with treatment responses
compared to 18.8% for other STS [28].
One-year PFS outcomes to first-line treatment were reported in locally advanced and/or metastatic
disease by Vlenterie. One-year PFS was highest in patients who received CYVADIC (23.3%) [28]. The
longest median PFS was 7.5 months in the Dox + Ifo treatment group. Greatest one-year OS outcomes
were also achieved in the Dox + Ifo subgroup (66.3%) but the longest median duration for OS was 15.8
months in the CYVADIC group, reported in a trial published in 1995 [28].
The most consistently reported time point for PFS and OS in mixed population studies was
at five years. Ferrari included patients with locally advanced (n = 40/271) or metastatic disease
(n = 16/271) and reported a five-year PFS of 36.8% for all patients; ten-year PFS was 29.8% [47]. Five
year OS across four studies ranged from 52% in an SS unspecified population reported by Corey [48]
to 69.8% in a mixed population receiving surgery and chemotherapy consisting primarily of Dox +
Ifo in Takenaka [30]. Deshmukh reported a ten-year OS of 42% in all patients in the cohort, which
included localized (n = 99/135), locally recurrent (n = 9/135) and metastatic (n = 27/135) patients [45].
3.3. Metastatic Disease
Five retrospective studies reported treatment response in patients with metastatic disease. In
Sanfilippo, a retrospective analysis of advanced SS patients in Italy, all patients (n = 61) treated with
trabectedin assessed were evaluable for response according to the RECIST criteria; 15% achieved a
partial response, and 35% had stable disease [49]. In a population where 89% had surgery in plus
systemic anti-cancer therapy five-year OS was 10% [46], and in a population where 92.5% had surgery
and 21.3% had radiotherapy in addition to systemic anti-cancer therapy five-year OS was 0% [30].
In a population where 90% received surgery and 71% received radiotherapy in addition to systemic
anti-cancer therapy, 15% of patients were alive at ten years [45].
METASARC is a prospective observational analysis of SS (n = 188) (Table 5). It was not captured
in the literature search due to the absence of a SS term in title or abstract, but included here due to its
importance. The analysis consisted of metastatic patients, 80% of whom were treated with systemic
anti-cancer therapy and 49% underwent a locoregional treatment of the metastasis: five-year OS was
7.14% [50], consistent with observations reported in retrospective studies in this literature review.
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Cohort (N) Treatment Arm




Reference for HR (95% CI)
Time,
Months Rate, % (95% CI)
Median, Months
(95% CI) Rate, % (95% CI)
Relapse/refractory




142 38 Pazopanib 5.3 (2.6, 6.3) – – – – 10.2 (7.5, 13.3) NR
Locally advanced or metastatic





– – – 36 56.3 (SD: 12) – 81.3 (SD:10)
Metastatic disease
Chugh, 2009 [55] 185 22 Imatinib 1.92 (1.92, 3.96) – – – – – –
Kawai, 2015 [56] 76 7 Trabectedin NR Trabectedin vs. BSC 0.14 (0.03, 0.68) – – – –
Mir, 2016
(REGOSARC) [57] 90 13 Regorafenib 5.6 (1.4, 11.6)
Regorafenib vs.
placebo 0.10 (0.03, 0.35) 3 77 (42, 92) 13.4 (5.3, NR) 92
Regorafenib – – – 6 38 (14, 63) – 77
Regorafenib – – – 9 38 (14, 63) – –
92 14 Placebo 1.0 (0.8, 1.4) – – 3 0 6.7 (2.2, NR) 85
Placebo – – – 6 0 – 64
Placebo – – – 9 0 – –
Ray—Coquard,
2008 [58] 48
b 46 Gefitinib 1.4 – – – –
Schoffski, 2011 [59] 128 19 Eribulin mesylate 2.6 (2.3, 4.3) – – 3 21.1 – 71.1 (43.7, 86.8)
Schoffski, 2013 [60] 111 17 Cixutumumab 1.5 (1.3, 2.6) – – 3 21.4 (5.2, 44.8) 13.0 (5.1, 16.5) 94.1 (65, 99.1)
Van der Graaf, 2012
(PALETTE) [61] 369 30 Pazopanib – SS vs. other STS 0.82 (0.51, 1.32) – – – –
Abbreviations: ‘–’ = Not reported; BSC = Best supportive care; EORTC = European Organisation for Research and Treatment of Cancer; IFO + Epi = Ifosfamide and epirubicin; NR = Not
reached; SS = Synovial sarcoma; STS = Soft-tissue sarcoma. a Given with granulocyte stimulating factor; b was solely a SS cohort, but only 46 evaluable for efficacy endpoint.
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4. Discussion
The number of STS subtypes recognized as distinct entities is growing, including myxoid
liposarcoma [62,63], undifferentiated pleomorphic sarcoma [4], and malignant peripheral nerve
sheath tumor [64]. Subtype-specific treatments demonstrating superior outcomes include eribulin
in liposarcoma [65], gemcitabine plus dacarbazine in leiomyosarcoma [66], and trabectedin in both
liposarcoma and leiomyosarcoma [67,68]. Recently pembrolizumab showed responses in patients with
undifferentiated pleomorphic sarcoma or dedifferentiated liposarcoma [69], also; both gemcitabine
alone and gemcitabine-docetaxel appeared to be active in leiomyosarcoma [70].
SS is a distinct subtype needing a tailored approach for management and further research; the
identification of a specific genetic alteration suggests targeted therapy could be of greater value than
conventional therapy [15]. Due to a lack of data, no consensus guidelines exist regarding the optimal
agents, sequencing or number of cycles of systemic anti-cancer therapy for SS. As a rare tumor type it
lacks funding to conduct an adequately powered randomized study to address the question of which
agents and sequencing are optimal to treat this disease.
SS is frequently identified as a chemosensitive STS; in 1994 an original publication of 13 patients
with recurrent or metastatic disease treated with high dose ifosfamide reported a response in all
patients [71]. A retrospective review of advanced SS patients using RECIST found Dox + Ifo achieved
responses at a higher rate compared to single agent doxorubicin or ifosfamide; however these results
may have been confounded by the use of metastectomies [25]. There are no published prospective
clinical trials that document SS as being more chemosensitive than the broad group of STS [72].
Few studies included linked specific anti-cancer therapy regimens with survival outcomes; most
aggregated survival outcomes into a single estimate of efficacy for the studied population, rather than
outcomes being reported independently by each agent or for the enrolled SS cohort. This makes it
difficult to determine which anti-cancer therapy may be driving the survival benefit or outcomes for
the SS cohort reported in the studies included in this review.
A recent study by Wang calculated an aggregate five-year OS of localized and metastatic SS
patients from the SEER registry for the years 2002 to 2013 to be 60.5% regardless of line of therapy [7].
Almost half of the 12 studies (5/12) we identified in this review that presented five-year OS for
mixed populations of localized and advanced stage patients reported proportions of survivors that
were within 5 percent points of this value (range: −8.5% to +11.5%). The SEER study also showed
significantly shorter survival for patients with distant compared to localized stage SS, with median
OS not reached among those with localized disease, and median OS with distant disease of under 20
months [7].
A limitation observed in the results of the SLR was the restricted number of prospective studies
identified for inclusion. There were two reasons for this: first, the eligibility criteria of the review
required that at least 50 SS patients were reported in a study. Secondly, the design of prospective
studies in STS, which frequently recruit numerous sarcoma histologies, meaning that data for SS are
available either only for a small cohort of patients (<50 SS participants), or that the data from the SS
patients are incorporated in the overall STS results. In the conduct of this systematic review with
a specific focus on SS, results reported in this way were not captured. Thus, the current available
evidence can only be based on studies including all STS histological subtypes. As knowledge of the
differences and molecular heterogeneity of the specific subtypes increases, the development of clinical
trials is moving towards study designs for specific histologic subtypes. In current practice, data from
prospective STS clinical trials are used to inform treatment practice for SS.
Beyond the limitations of the review, the data reported in this SLR also have multiple limitations
that should be considered when evaluating the reported results. They include but are not limited to the
following: the majority of patients were treated prior to either RECIST v1.0 or v1.1 and the definition
of responses are not always provided nor systematically applied; imaging methods were not consistent
nor is it known if trained radiologists evaluated the response assessments; there is selection bias as
to which systemic anti-cancer therapy was administered and the dose intensity is not reported; there
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was heterogeneity of patients treated in studies including locally advanced and metastatic disease;
the majority of reported results are from retrospective or observational studies and as such there is no
reporting of how data was censored or if data was source verified.
In order to mitigate the limitations which led to the paucity of data from the SLR, we evaluated
data from trials which combined multiple histologies. From this we compiled prospective studies
of systemic anti-cancer treatments that included a cohort of fewer than 50 SS patients as part of the
STS enrolled population, and the key survival results they provided. Due to the focus on systemic
treatment, the majority of these identified prospective studies (7/10) had recruited patients with
metastatic disease. One study focused on locally advanced and metastatic [54] and two on relapsed or
refractory disease [53,54].
The number of SS patients included in the prospective studies ranged from 7 to 38 (Table 5).
Only two of the prospective studies reported outcomes beyond one year, which are compared to
the outcomes presented in the studies identified in our SLR. Three-year PFS and OS was 56.3% and
81.3% for pediatric and adolescent patients treated with neoadjuvant vincristine, Dox + Ifo for locally
advanced disease [54].
Across all relapsed/refractory and metastatic studies, median OS ranged from 6.7 to 13.4 months
and PFS ranged from 1.0 to 5.6 months, respectively, in the maintenance study of placebo versus
regorafenib arms of the REGOSARC trial [57].
Currently no standard approach exists for the use of systemic anti-cancer therapy in SS, neither
are there studies that evaluate what sequencing of agents is recommended. An anthracycline plus
ifosfamide combination is often considered in the first line treatment as it has a high response rate
in STS [72]. However, the recent approval of olaratumab has led to the consideration of doxorubicin
in combination with olaratumab as an alternate option in the anthracycline naive setting [73,74].
Treatment decisions tend to be made based on retrospective data and the treating physician and patient
preferences to provide the best tumor outcomes and optimize the risk to benefit ratio. Clinical features
including age, tumor size and location are also used in selecting an optimal regimen [14,33]. The use of
adjuvant/neoadjuvant chemotherapy remains controversial as there are no definitive trials to support
its use in practice, and a recent large multicenter histology driven use of neoadjuvant did not show
benefit over standard systemic anti-cancer therapy [51]. However, factors associated with receipt of
adjuvant chemotherapy were age <30, primary extremity site, grade 3 histology, tumor size >5cm and
positive surgical margins [33].
5. Conclusions
SS represents 5–10% of all STS; as a result, published literature often does not focus on the specific
histology, but rather reports on patients with SS as part of the larger STS group. There is a need to
further understand the biology and develop novel therapeutics for this distinct subtype as well as
to understand tumor genomics and mechanisms of resistance. Current clinical practice is to treat SS
based on evidence from published prospective clinical trials that enrolled multiple subtypes of STS.
This SLR has multiple limitations and is not generalizable; but gives an overview of the available
data for the use of current systemic anti-cancer therapy options for treatment planning for patients
with SS. Additional multi-center and global prospective observational studies and randomized clinical
trials to better define the most appropriate treatment for SS in all stages and lines of therapy are still
needed. Areas of future research cover a broad range of treatments including targeted therapies e.g.,
NY-ESO-1-directed therapies, tyrosine kinase inhibitors, Adoptive Cell therapies, epigenetics e.g.,
HDAC and EZH2 inhibitors, chromatin remodeling and metabolic pathways.
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